[go: up one dir, main page]

NO328628B1 - Fremgangsmate for syntetisering av camptothecin relaterte forbindelser - Google Patents

Fremgangsmate for syntetisering av camptothecin relaterte forbindelser Download PDF

Info

Publication number
NO328628B1
NO328628B1 NO20033579A NO20033579A NO328628B1 NO 328628 B1 NO328628 B1 NO 328628B1 NO 20033579 A NO20033579 A NO 20033579A NO 20033579 A NO20033579 A NO 20033579A NO 328628 B1 NO328628 B1 NO 328628B1
Authority
NO
Norway
Prior art keywords
compound
mixture
reagent
accordance
stirring
Prior art date
Application number
NO20033579A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033579D0 (no
NO20033579L (no
Inventor
Takanori Ogawa
Hiroyuki Nishiyama
Miyuki Uchida
Seigo Sawada
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of NO20033579D0 publication Critical patent/NO20033579D0/no
Publication of NO20033579L publication Critical patent/NO20033579L/no
Publication of NO328628B1 publication Critical patent/NO328628B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20033579A 2001-02-21 2003-08-13 Fremgangsmate for syntetisering av camptothecin relaterte forbindelser NO328628B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001045430 2001-02-21
JP2001309322 2001-10-05
PCT/JP2002/001538 WO2002066416A1 (en) 2001-02-21 2002-02-21 Method of synthesizing camptothecin-relating compounds

Publications (3)

Publication Number Publication Date
NO20033579D0 NO20033579D0 (no) 2003-08-13
NO20033579L NO20033579L (no) 2003-10-10
NO328628B1 true NO328628B1 (no) 2010-04-12

Family

ID=26609837

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20033579A NO328628B1 (no) 2001-02-21 2003-08-13 Fremgangsmate for syntetisering av camptothecin relaterte forbindelser
NO20093402A NO331656B1 (no) 2001-02-21 2009-11-24 Framgangsmate for syntetisering av camptothesin relaterte forbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20093402A NO331656B1 (no) 2001-02-21 2009-11-24 Framgangsmate for syntetisering av camptothesin relaterte forbindelser

Country Status (23)

Country Link
US (2) US7126000B2 (ro)
EP (1) EP1378505B1 (ro)
JP (2) JP4210119B2 (ro)
KR (2) KR100864692B1 (ro)
CN (1) CN100408550C (ro)
AR (2) AR035684A1 (ro)
AU (1) AU2002237527B2 (ro)
BG (2) BG108031A (ro)
BR (1) BR0207470A (ro)
CA (2) CA2683768C (ro)
CZ (1) CZ20032470A3 (ro)
EE (1) EE05361B1 (ro)
HU (1) HUP0302755A3 (ro)
IL (2) IL156949A0 (ro)
MX (1) MXPA03007528A (ro)
NO (2) NO328628B1 (ro)
NZ (2) NZ527615A (ro)
PL (2) PL217238B1 (ro)
RO (2) RO122639B9 (ro)
RU (1) RU2308447C2 (ro)
SK (2) SK288149B6 (ro)
TW (1) TWI245768B (ro)
WO (1) WO2002066416A1 (ro)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
JP2008509211A (ja) * 2004-08-09 2008-03-27 シルパ・メディケア・リミテッド 塩酸イリノテカン三水和物の改良された製造方法
EP1824485B1 (en) * 2004-11-05 2012-09-19 Samyang Biopharmaceuticals Corporation Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents
ATE446299T1 (de) * 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
US7767813B2 (en) * 2005-02-08 2010-08-03 Fermion Oy Preparation method
WO2006084940A1 (en) 2005-02-08 2006-08-17 Fermion Oy Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
US8112154B2 (en) * 2005-04-13 2012-02-07 The Cleveland Clinic Foundation Systems and methods for neuromodulation using pre-recorded waveforms
TWI375678B (en) * 2005-06-09 2012-11-01 Yakult Honsha Kk A method of preparation of a tricyclic ketone
EP1910269B1 (en) * 2005-08-03 2013-09-18 Avra Laboratories PVT. Ltd. Method of synthesizing key intermediates for the production of camptothecin derivatives
EP1803725A1 (en) * 2005-12-13 2007-07-04 W.C. Heraeus GmbH Methods for preparing irinotecan
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
CN101824038B (zh) * 2009-03-06 2013-08-21 复旦大学 喜树碱及其类似物的制备方法
WO2011025865A1 (en) 2009-08-27 2011-03-03 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
JP5599094B2 (ja) * 2010-05-20 2014-10-01 国立大学法人 千葉大学 ニトリル化合物の製造方法
CA2802708A1 (en) 2010-06-14 2011-12-22 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
US8751008B2 (en) 2011-08-09 2014-06-10 Boston Scientific Neuromodulation Corporation Remote control data management with correlation of patient condition to stimulation settings and/or with clinical mode providing a mismatch between settings and interface data
EP2890454B1 (en) 2012-08-28 2017-11-08 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US8722886B1 (en) * 2012-11-13 2014-05-13 Bionumerik Pharmaceuticals, Inc. Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US9974959B2 (en) 2014-10-07 2018-05-22 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
SG11201702105QA (en) * 2014-10-22 2017-05-30 Vivacitas Oncology Inc Methods and systems for camptothecin analog synthesis
JP6481051B2 (ja) 2015-05-26 2019-03-13 ボストン サイエンティフィック ニューロモデュレイション コーポレイション 電気刺激を分析し活性化容積を選択又は操作するシステム及び方法
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
EP3280490B1 (en) 2015-06-29 2021-09-01 Boston Scientific Neuromodulation Corporation Systems for selecting stimulation parameters based on stimulation target region, effects, or side effects
ES2940303T3 (es) 2015-06-29 2023-05-05 Boston Scient Neuromodulation Corp Sistemas de selección de parámetros de estimulación por uso de dianas y direccionamiento
EP3359252B1 (en) 2015-10-09 2020-09-09 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulations leads
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
JP6905541B2 (ja) 2016-06-24 2021-07-21 ボストン サイエンティフィック ニューロモデュレイション コーポレイション 臨床効果の視覚分析のためのシステム及び方法
WO2018044881A1 (en) 2016-09-02 2018-03-08 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
AU2017341910B2 (en) 2016-10-14 2020-05-14 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
US10792501B2 (en) 2017-01-03 2020-10-06 Boston Scientific Neuromodulation Corporation Systems and methods for selecting MRI-compatible stimulation parameters
ES2821752T3 (es) 2017-01-10 2021-04-27 Boston Scient Neuromodulation Corp Sistemas y procedimientos para crear programas de estimulación en base a áreas o volúmenes definidos por el usuario
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
US11357986B2 (en) 2017-04-03 2022-06-14 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
AU2018301355B2 (en) 2017-07-14 2020-10-01 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
WO2019036180A1 (en) 2017-08-15 2019-02-21 Boston Scientific Neuromodulation Corporation SYSTEMS AND METHODS FOR CONTROLLING ELECTRICAL STIMULATION USING MULTIPLE STIMULATION FIELDS
CN112041022B (zh) 2018-04-27 2024-07-02 波士顿科学神经调制公司 多模式电刺激系统及其制造和使用方法
WO2019210214A1 (en) 2018-04-27 2019-10-31 Boston Scientific Neuromodulation Corporation Systems for visualizing and programming electrical stimulation
EP3911660B1 (en) * 2019-01-15 2023-05-10 Laurus Labs Limited Process for preparation of 2-amino-5-hydroxy propiophenone
CN118108705A (zh) * 2024-01-29 2024-05-31 浙江工业大学 一种富马酸沃诺拉赞的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
JPH07101956A (ja) * 1993-10-05 1995-04-18 Tanabe Seiyaku Co Ltd ヒドロキシカンプトテシン化合物の製法
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
JPH08225482A (ja) * 1995-02-22 1996-09-03 Dai Ichi Seiyaku Co Ltd テトラロン関連化合物及びその製法
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US6143891A (en) 1995-11-02 2000-11-07 Glaxo Wellcome Inc. Method for preparing camptothecin derivatives
SG116433A1 (en) 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.

Also Published As

Publication number Publication date
SK288073B6 (sk) 2013-05-03
AU2002237527B2 (en) 2007-01-04
NZ534374A (en) 2004-12-24
NO331656B1 (no) 2012-02-13
BR0207470A (pt) 2008-04-08
AR035684A1 (es) 2004-06-23
RO122639B1 (ro) 2009-10-30
US20040106830A1 (en) 2004-06-03
EE05361B1 (et) 2010-12-15
EP1378505A1 (en) 2004-01-07
HUP0302755A2 (hu) 2003-12-29
CZ20032470A3 (cs) 2004-02-18
PL218065B1 (pl) 2014-10-31
MXPA03007528A (es) 2003-12-11
AR082663A2 (es) 2012-12-26
NZ527615A (en) 2004-12-24
RU2308447C2 (ru) 2007-10-20
KR100864692B1 (ko) 2008-10-23
JP4210119B2 (ja) 2009-01-14
SK288149B6 (sk) 2013-12-02
RO125158A2 (ro) 2010-01-29
IL156949A (en) 2009-09-01
US7126000B2 (en) 2006-10-24
HUP0302755A3 (en) 2008-03-28
CN1492851A (zh) 2004-04-28
PL217238B1 (pl) 2014-06-30
TWI245768B (en) 2005-12-21
SK11472003A3 (sk) 2004-03-02
IL156949A0 (en) 2004-02-08
CA2683768C (en) 2013-05-28
PL399009A1 (pl) 2012-09-10
BG111453A (en) 2013-09-30
BG108031A (bg) 2005-04-30
KR20080012383A (ko) 2008-02-11
KR20030077631A (ko) 2003-10-01
PL363440A1 (en) 2004-11-15
CN100408550C (zh) 2008-08-06
CA2437702C (en) 2010-04-06
JP2008273952A (ja) 2008-11-13
CA2683768A1 (en) 2002-08-29
NO20033579D0 (no) 2003-08-13
RU2003128530A (ru) 2005-03-27
EE200300373A (et) 2003-10-15
NO20093402L (no) 2003-10-10
JPWO2002066416A1 (ja) 2004-09-24
US7378555B2 (en) 2008-05-27
EP1378505A4 (en) 2006-09-27
WO2002066416A1 (en) 2002-08-29
JP4805967B2 (ja) 2011-11-02
EP1378505B1 (en) 2014-11-05
RO122639B9 (ro) 2014-03-28
KR100858972B1 (ko) 2008-09-17
CA2437702A1 (en) 2002-08-29
US20070010674A1 (en) 2007-01-11
NO20033579L (no) 2003-10-10

Similar Documents

Publication Publication Date Title
NO328628B1 (no) Fremgangsmate for syntetisering av camptothecin relaterte forbindelser
US5446047A (en) Camptothecin analogues
JP5762624B2 (ja) 安定な７員環ラクトンを含むカンプトテシン化合物、それらの製造方法及び使用
Manoer et al. Synthesis of bis chalcones and transformation into bis heterocyclic compounds with expected antimicrobial activity
CA2591071C (en) Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
Ershov et al. Reaction of 4-aryl-2-aminobuta-1, 3-diene-1, 1, 3-tricarbonitriles with CH-nucleophiles: I. Synthesis of 5-aryl-2, 4-diamino-8, 8-dimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5 H-chromeno [2, 3-b] pyridine-3-carbonitriles
Ashok et al. Solvent-free microwave assisted synthesis of morpholine–piperidine–pyrrolidine annulated quinoline-naphthyl based chalcones and their antimicrobial activity
Jin et al. Solid state synthesis of 5-oxo-1, 4, 5, 6, 7, 8-hexahydroquinoline derivatives without using solvent and catalyst
WO2006129781A1 (ja) ジベンズオキセピン誘導体の製造方法
USRE41366E1 (en) Total synthesis of galanthamine, analogues and derivatives thereof
OHTA et al. Synthetic approaches to 3-amino-1, 4-naphthoquinone-2-carboxylic acid derivatives and photochemical synthesis of novel 1, 4, 5, 10-tetrahydro-5, 10-dioxo-2H-naphth [2, 3-d][1, 3] oxazine derivatives
Fang et al. Synthesis of 6, 7-Dihydrodibenzo [b, j] phenanthroline Derivatives by Pfitzinger Condensation of Isatin and Cyclic Diketones
Saad Environmentally benign synthesis of 2-pyrazolines and cyclohexenones incorporating naphthalene moiety and their antimicrobial evaluation
Moskalenko et al. Synthesis of N-arylmethyl-3-azabicyclo [3.3. 1] nonan-9-ones.
KR101355121B1 (ko) 캄토테신의 입체선택적 방법 및 결정성 형태
Hu et al. Facile synthesis of novel tacrine analogues
Wang et al. An improved synthesis of reduced 9-arylacridine-1, 8-diones from 3-amino-5, 5-dimethylcyclohex-2-enone, arylaldehydes and 1, 3-dicarbonyl compounds in aqueous medium
Angel-Jijón et al. Light induced cyclization of tryptamine-naphthoquinone hybrids.
KR101471943B1 (ko) 7-히드록시-3'',4'',5-트리메톡시플라본의 제조방법
JP5863846B2 (ja) イリノテカンの製造方法
Chantegrel et al. Synthesis of 3‐alkenyl‐4‐oxo‐6, 7‐dihydro‐1H‐pyrano [4, 3‐c] pyrazole derivatives
Sagitullina et al. Novel Approach to Synthesis of meta-Terphenyls.
JPH0670029B2 (ja) 新規ビスベンゾフラン誘導体およびその製造法
JP2006199600A (ja) アルコキシピペリジン誘導体の製造法

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees